Korean J Hematol 1997; 32(3):
Published online September 30, 1997
© The Korean Society of Hematology
이은정, 이경희, 현명수
영남대학교 의과대학 내과학교실
Background: Although multiple myeloma is known to be a hematologic malignancy which cannot be cured, MP(melphaln, prednisone) based combination chemotherapy can prolong survival and improve quality of life for myeloma patients. The purpose of this report is to analyse chemotherapeutic effect and prognostic factors in myeloma patients.
Methods: Between March, 1983 and March, 1995 at Yeungnam University Hospital 45 patients were diagnosed as multiple myeloma by SWOG criteria. Thirty-four of 45 patients were treated with MP chemotherapy.
Results:
1) The peak incidence was in 6th decade(20%) and male to female ratio was 2.2:1. The most common presenting symptom at first diagnosis was bone pain(55%).
2) Seventy one percent of the patients were clinical stage Ⅲ. Performance status(ECOG scale) was grade 3 in 64%, grade 2 in 12%, grade 1 in 9% of the patients.
3) Hematologic findings showed anemia(Hb<8.5g/dL) in 40%, leukopenia in 27%, thrombocytopenia in 27% and increased ESR in 72% of the patients. Hypercalcemia was noted in 11% and renal failure in 29%. Serum immune electrophoresis revealed myeloma protein as IgG in 67%, light chain only in 24%, IgA in 9%, and kappa to lambda ratio was 1:2.6.
4) The median survival of chemotherapy group was 84 weeks and that of non-treatment group was 7 weeks. Response rate to MP chemotherapy was 35%, median response duration was 78 weeks. There was statistically significant survival
difference between responder and non-responder(187 weeks to 27 weeks)(P<0.001).
5) Patients with ECOG grade>3, hypercalcemia, renal insufficiency, beta-2 microglobulin>4㎍/mL, non-treatment group, non-responder had lower survival time.
Conclusion: These results suggest that there is no prospect of cure with MP-based chemotherapy, but the survival benefit is meaningful for patients with chemotherapy responder. More intensive treatment, especially myeloablative treatment with bone marrow or peripheral blood stem cell transplantation should be investigated, considering curability.
Keywords Multiple myeloma; MP-chemotherapy; Clinical characteristics;
Korean J Hematol 1997; 32(3): 409-418
Published online September 30, 1997
Copyright © The Korean Society of Hematology.
이은정, 이경희, 현명수
영남대학교 의과대학 내과학교실
Eun Jung Lee, Kyung Hee Lee, Myung Soo Hyun
Department of Internal Medicine, College of Medicine, Yeungnam University, Taegu, Korea
Background: Although multiple myeloma is known to be a hematologic malignancy which cannot be cured, MP(melphaln, prednisone) based combination chemotherapy can prolong survival and improve quality of life for myeloma patients. The purpose of this report is to analyse chemotherapeutic effect and prognostic factors in myeloma patients.
Methods: Between March, 1983 and March, 1995 at Yeungnam University Hospital 45 patients were diagnosed as multiple myeloma by SWOG criteria. Thirty-four of 45 patients were treated with MP chemotherapy.
Results:
1) The peak incidence was in 6th decade(20%) and male to female ratio was 2.2:1. The most common presenting symptom at first diagnosis was bone pain(55%).
2) Seventy one percent of the patients were clinical stage Ⅲ. Performance status(ECOG scale) was grade 3 in 64%, grade 2 in 12%, grade 1 in 9% of the patients.
3) Hematologic findings showed anemia(Hb<8.5g/dL) in 40%, leukopenia in 27%, thrombocytopenia in 27% and increased ESR in 72% of the patients. Hypercalcemia was noted in 11% and renal failure in 29%. Serum immune electrophoresis revealed myeloma protein as IgG in 67%, light chain only in 24%, IgA in 9%, and kappa to lambda ratio was 1:2.6.
4) The median survival of chemotherapy group was 84 weeks and that of non-treatment group was 7 weeks. Response rate to MP chemotherapy was 35%, median response duration was 78 weeks. There was statistically significant survival
difference between responder and non-responder(187 weeks to 27 weeks)(P<0.001).
5) Patients with ECOG grade>3, hypercalcemia, renal insufficiency, beta-2 microglobulin>4㎍/mL, non-treatment group, non-responder had lower survival time.
Conclusion: These results suggest that there is no prospect of cure with MP-based chemotherapy, but the survival benefit is meaningful for patients with chemotherapy responder. More intensive treatment, especially myeloablative treatment with bone marrow or peripheral blood stem cell transplantation should be investigated, considering curability.
Keywords: Multiple myeloma, MP-chemotherapy, Clinical characteristics,
Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung-Chul Mun, Sung-Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon-Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho-Young Yhim, Yoon Hwan Chang, Jae-Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim and Kihyun Kim
Blood Res 2025; 60():Haerim Chung, Hyunsoo Cho
Blood Res 2023; 58(4): 166-172Ja Min Byun, Sung-Soo Park, Sung-Soo Yoon, Ari Ahn, Myungshin Kim, Jung Yeon Lee, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Youngil Koh, Chang-Ki Min
Blood Res 2023; 58(2): 83-90